What is Nuvation Bio?
Nuvation Bio operates as a global biopharmaceutical enterprise dedicated to the discovery and development of novel therapies for the most challenging oncology indications. The company distinguishes itself by targeting cancers where conventional treatment modalities have historically failed, focusing on innovative mechanisms of action that address significant gaps in current clinical practice. By leveraging a robust pipeline of differentiated product candidates, Nuvation Bio aims to transform the standard of care for patients with limited prognosis.
The firm's market position is bolstered by its strategic approach to biopharmaceutical innovation, which balances high-risk, high-reward research with rigorous clinical validation. As it scales its operations, the company continues to prioritize the development of therapies that offer meaningful clinical benefits, positioning itself as a key player in the next generation of precision oncology.
How much funding has Nuvation Bio raised?
Nuvation Bio has raised a total of $525M across 2 funding rounds:
Series A
$275M
Other Financing Round
$250M
Series A (2019): $275M with participation from Altitude Life Science Ventures, EDBI, Perceptive Advisors, The Baupost Group, Omega Funds, Redmile Group, Boxer Capital, Pavilion Capital, Surveyor Capital, Fidelity Management, Aisling Capital, and ECOR1 Capital
Other Financing Round (2025): $250M led by Sagard
Key Investors in Nuvation Bio
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991, with a mission to catalyze growth and transform industries through strategic investments.
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies, with over $1.8 billion in assets.
What's next for Nuvation Bio?
With the successful closure of this latest financing round, Nuvation Bio is well-positioned to accelerate its clinical development programs and expand its research capabilities. The strategic allocation of these funds will likely focus on advancing lead candidates through critical trial phases, potentially broadening the scope of its therapeutic pipeline. As the company transitions into this next phase of growth, the focus will remain on achieving key clinical milestones that validate its proprietary technology and enhance its long-term value proposition in the competitive biopharmaceutical market.
Furthermore, the continued support from a sophisticated investor base provides Nuvation Bio with the operational flexibility to explore potential partnerships or strategic initiatives that could further amplify its impact on global oncology care. The company remains committed to its core mission of delivering transformative solutions to patients, ensuring that its capital deployment is aligned with long-term scientific and commercial success.
